Association of NF-{kappa}B polymorphisms with clinical outcome of non-medullary thyroid carcinoma

In conclusion, genetic variation in NFKBIA, an inhibitor of NF-B signaling, is associated with clinical response to RAI therapy and with increased production of the pro-inflammatory cytokine IL-1β, providing a potential mechanism for the observed clinical associations. These data suggest that NF-B signaling is involved in NMTC pathogenesis and that the inflammatory tumor microenvironment could contribute to RAI resistance.

Source: Endocrine-Related Cancer - July 3, 2017 Category: Endocrinology Authors: Plantinga, T. S., Petrulea, M. S., Oosting, M., Joosten, L. A. B., Piciu, D., Smit, J. W., Netea-Maier, R. T., Georgescu, C. E. Tags: Research Source Type: research